Hospitals buying doctor offices and steering prescriptions to their own pharmacies are adding new fees and higher prices to family medical bills, with Medicare and seniors paying more.
Story Highlights
- Medicare’s own advisors say hospital takeovers of clinics trigger extra “facility” fees and higher payment rates.
- Past MedPAC work found physician–hospital integration raises both commercial and Medicare prices for the same services.
- Experts warn integrated pharmacy benefit chains can steer costly drugs to in-house pharmacies and boost reimbursements.
- Congressional analysts note some drug savings inside insurer–pharmacy benefit mergers, but not across all patients.
Hospital Ownership Drives Higher Bills Through Site-Based Fees
The Medicare Payment Advisory Commission reported that when a hospital buys a physician practice, the hospital can bill a facility fee on top of the doctor’s fee. That happens each time a Medicare patient is seen in the hospital-owned clinic. Those add-on charges stem from site-based payment rules that pay more for the same service done in a hospital setting. MedPAC concluded these differentials raise program spending and beneficiary costs through higher coinsurance and deductibles.
MedPAC’s findings match what many seniors feel at the counter. Patients who see the same doctor in the same building after a takeover can get a surprise line item labeled “facility.” That fee is not tied to better care. It is tied to ownership status and billing rules. Higher allowed charges mean higher out-of-pocket costs. Fixed incomes get squeezed first. Taxpayers get the rest of the bill through higher Medicare spending.
Consolidation Raises Prices For Physician Services
Earlier analysis from the Medicare Payment Advisory Commission found that vertical physician–hospital consolidation increases prices paid for physician services by both commercial plans and Medicare. The price jump does not come from a new cure or a better test. It comes from market leverage and billing changes after a deal closes. When a large system owns the doctor group, it can command more, and payers often pass those costs to families through premiums and cost sharing.
These ownership links also change where care happens. Hospitals can move routine visits, imaging, and labs into higher-priced settings inside their systems. That shift boosts revenue even if the service is the same. MedPAC has urged site-neutral reforms so payers stop rewarding location over value. Without reform, seniors and working families pay more for identical care, and smaller independent practices struggle to compete on an uneven field.
Pharmacy Steering And Specialty Drug Costs Inside Integrated Chains
Congressional testimony highlighted that the Federal Trade Commission’s 2024 work on pharmacy benefit managers described steering of specialty prescriptions to affiliated pharmacies. The testimony said vertically integrated supply chains can also pay higher reimbursements to in-house pharmacies. That kind of steering narrows choice and can raise patient costs when networks push people away from lower-priced options that are outside the corporate family.
Americans already face high drug prices and complex formularies. When the same parent company controls the health plan, the pharmacy benefit manager, and the pharmacy, the incentives can tilt toward keeping dollars inside the chain. Patients often cannot see the real price. They only feel the copay, the deductible hit, or the denial. This black box hurts trust and makes it harder for families to shop for a fair deal.
What The Congressional Budget Office Says About Drug Prices
The Congressional Budget Office said that when insurers merge with pharmacy benefit managers, aligned incentives can lower drug prices for patients who are inside those vertically integrated health plans. That is a real but narrow effect. It does not mean everyone pays less. Patients outside those plans, or using unaffiliated pharmacies, may not see the same savings. Some mergers could also raise costs in other parts of the system.
For conservatives, the takeaway is simple. Centralized power without transparency rarely serves the patient. Real competition and clear pricing help families. Site-neutral payment can stop games that reward billing tricks over patient value. Strong oversight can deter steering that limits pharmacy choice. President Trump’s team can drive rules that protect seniors, defend free markets, and end hidden fees that drain savings and federal budgets at the same time.
Bottom Line For Patients And Policymakers
Medicare’s advisors and multiple analyses tie vertical consolidation to higher prices for the same care. Facility fees and referral steering shift dollars from families to corporate systems. Some narrow drug savings exist inside certain integrated plans, but they do not erase broader price hikes across services. Lawmakers should press for site-neutral payment, sunlight in pharmacy benefit contracts, and freedom for independent doctors and pharmacies to compete on price and quality.
Sources:
medpac.gov, warren.senate.gov, congress.gov, sciencedirect.com
